Related Experiment Videos
[Safety evaluation of micronomicin IX. Perinatal and postnatal study by intravenous injection in rats]
Abstract:
Micronomicin (MCR) is a new aminoglycoside antibiotic produced by Micromonospora sagamiensis var. nonreducans which was isolated from soil collected at Sagamihara City by Nara et al. This antibiotic shows a close similarity to gentamicin C components in physical and chemical properties. The antibacterial activity of MCR is broad-spectrum and almost equal to that of gentamicin C complex. MCR exhibits particularly high activity against Pseudomonas, Proteus, Klebsiella pneumoniae, Serratia, etc. as well as against some Pseudomonas aeruginosa strains resistant to gentamicin C1a. Perinatal and postnatal studies of MCR in rats were carried out by intravenous injection for safety evaluation (Dose; 25, 50 mg/kg and 75 mg/kg). The results of studies are as follows. There was no adverse effect on delivery and nursing ability in dams at any dose. There was no adverse effect at any dose on postnatal development of offspring, such as weight gain, postnatal differentiation, spontaneous motor activity, learning, sexual maturation and reproductive performance. Renal toxicity was observed at dose of 75 mg/kg in autopsy of dams after treatment.
Insights
Micronomicin (MCR), a novel aminoglycoside antibiotic, shows broad-spectrum activity, including against gentamicin-resistant bacteria. While safe for perinatal and postnatal development in rats, high doses caused renal toxicity in dams.
Area of Science:
- Microbiology and Pharmacology
- Drug Discovery and Development
Context:
- Micronomicin (MCR) is a novel aminoglycoside antibiotic derived from Micromonospora sagamiensis var. nonreducans.
- It shares physical, chemical, and antibacterial properties with gentamicin C components.
- MCR demonstrates broad-spectrum activity, particularly against challenging pathogens like Pseudomonas and gentamicin-resistant Pseudomonas aeruginosa.
Purpose:
- To evaluate the safety and efficacy of Micronomicin (MCR) through perinatal and postnatal studies in rats.
- To assess the impact of MCR on maternal health, delivery, nursing, and offspring development.
- To identify potential toxicological effects, specifically renal toxicity, at varying dosages.
Summary:
- Perinatal and postnatal studies in rats involved intravenous administration of MCR at 25, 50, and 75 mg/kg.
- No adverse effects were observed on dam delivery, nursing ability, or offspring development (weight gain, motor activity, learning, maturation, reproduction).
- Renal toxicity was noted in dams at the highest dose (75 mg/kg) during autopsy.
Impact:
- Micronomicin (MCR) presents a promising antibiotic candidate with potent activity against resistant bacterial strains.
- The safety profile suggests potential therapeutic applications, with careful consideration of dosage to mitigate renal toxicity.
- Further research can explore MCR's clinical efficacy and pharmacokinetic properties.